When Your GLP-1 Isn't Working: The Clinical Playbook for Plateaus

The Plateau Is Normal — Your Response to It Matters

You have been on a GLP-1 medication for months. You lost weight steadily at first — maybe 15, 20, even 30 pounds. Then the scale stopped. It has been weeks, maybe longer, without meaningful change. You are still taking your medication, still eating well. What is happening?

Weight-loss plateaus on GLP-1 therapy are not a sign of failure. They are a predictable physiological response that occurs in virtually every patient. The question is not whether you will plateau — it is what your doctor should do about it.

Why Plateaus Happen

Several mechanisms converge to slow weight loss after the initial rapid phase:

• Metabolic adaptation. As you lose weight, your body requires fewer calories to maintain basic functions. A patient who weighed 250 pounds burns significantly more calories at rest than the same patient at 210 pounds. Your metabolism literally slows down to match your new size.
• Hormonal recalibration. Leptin (the satiety hormone) decreases as fat stores shrink, while ghrelin (the hunger hormone) may increase. GLP-1 medications counteract these signals, but the body's compensatory drive is powerful.
• Dose ceiling. If you are at the maximum dose of your current medication and have been for several months, the drug's weight-loss effect may have plateaued. The body develops some degree of physiological accommodation to the medication.
• Body composition shift. Even when the scale is not moving, your body composition may still be improving — losing fat while maintaining or slightly gaining lean mass. This is actually a good outcome, but it does not show on a standard scale.

The Clinical Playbook for Breaking a Plateau

Here is what your doctor should evaluate, in order:

Step 1: Confirm You Are at Therapeutic Dose

This sounds obvious, but many patients plateau because they never reached the full therapeutic dose. Titration schedules are slow for good reason (managing side effects), but if you have been at a sub-maximal dose for months without side effects, you may have room to increase.

Step 2: Consider the Step-Up to Wegovy HD 7.2mg

For patients on semaglutide 2.4mg who have tolerated it for at least four weeks, the newly approved 7.2mg dose offers a specific, FDA-sanctioned step-up option. The STEP UP trial showed patients lost an additional 3.2 percentage points of body weight by moving from 2.4mg to 7.2mg.

Step 3: Evaluate a Medication Switch

Switching drug classes — from semaglutide to tirzepatide, or vice versa — is a well-established clinical strategy for patients who have plateaued. The mechanisms of action differ enough that patients who have maxed out their response to one medication often respond to another.

Step 4: Check for Confounding Factors

Request labs: thyroid function (TSH, free T4), cortisol (if Cushing's is suspected), comprehensive metabolic panel, and A1C. Certain medications can also blunt GLP-1 response — corticosteroids, some antidepressants, antipsychotics, and insulin can all promote weight gain or stall weight loss.

Step 5: Reassess Lifestyle Factors

Sleep quality (poor sleep increases cortisol and hunger hormones), stress levels, physical activity changes, and gradual calorie creep can all contribute to plateaus. These are not character flaws — they are modifiable variables that your clinical team should help you address.